Venture capital alone is no longer enough to power the next wave of biotechnology innovation. Across health, biosecurity, climate, and advanced biomanufacturing, government agencies are emerging as catalytic partners, deploying billions in non-dilutive funding to accelerate high-risk, high-impact breakthroughs. But accessing this capital requires more than strong science. Founders must understand how agencies like ARPA-H, DARPA, BARDA, and others evaluate risk, define mission impact, and structure partnerships that bridge research and real-world deployment. This session brings together agency leaders, founders, and experienced operators to demystify how government funding actually works in today’s market. The panelists will explore how startups can position themselves for success, avoid common pitfalls in proposal development and contracting, and strategically leverage non-dilutive funding to extend runway, de-risk technology, and unlock new commercial pathways.